Study of a new drug for advanced stomach cancer after prior treatments
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced stomach or gastroesophageal junction cancer that has worsened after at least two prior treatments.
- A tumor sample shows your cancer has the CLDN18.2 protein at a certain level (tested by a central lab).
- You have at least one measurable tumor (largest tumor ≤5 cm) or an evaluable lesion.
- You are in generally good health (ECOG score 0 or 1) and expected to live at least 12 weeks.
- Your heart, liver, kidney, and blood counts meet safety thresholds.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called satri-cel for people with stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2) and has been removed by surgery. The goal is to see if this treatment can prevent the cancer from coming back.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug called CT0494BCP for advanced stomach cancer that has not responded to previous treatments. The drug targets a protein called CLDN18.2, which is found on many stomach cancer cells, and aims to help your immune system fight the cancer.
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
This trial tests an experimental cell therapy (IM96 CAR-T) for advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The therapy uses your own immune cells, modified in a lab to target a protein (GUCY2C) found on cancer cells, potentially helping your body fight the cancer.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.